An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C
NCT ID: NCT01604291
Last Updated: 2019-03-14
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
991 participants
OBSERVATIONAL
2012-05-28
2016-02-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Observational Study of Pegasys in Dual- or Triple-Therapy in Patients With Chronic Hepatitis C
NCT01679834
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
NCT01447446
A Study of PEGASYS (Peginterferon Alfa-2a) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3
NCT01258101
Efficacy and Safety of Peg-Interferon Alpha-2a Plus Ribavirin in Genotype 1 Chronic Hepatitis C Participants Co-Infected With Human Immunodeficiency Virus
NCT02761629
A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response
NCT01033448
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Chronic hepatitis C (all genotypes, naïve or treatment experienced, HCV mono-infected or HCV-HIV co-infected)
* Receiving either dual therapy (Pegasys plus ribavirin) or triple therapy (Pegasys plus ribavirin plus telaprevir/boceprevir)
* No contra-indications to Pegasys and ribavirin therapy or to treatment regimen containing protease inhibitor (telaprevir or boceprevir) as detailed in local Prescribing Information
* Quantitative serum HCV RNA by PCR test before initiation of treatment
Exclusion Criteria
* Evidence of severe illness, active malignancy, or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study
* Pregnant or breast-feeding women
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Clalit Health Services
OTHER
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rebecca Sieff Medical Center; Liver Unit
Safed, , Israel
Haemek Hospital; Gastroenterology
Afula, , Israel
Barzilai MC; Gastroenterology
Ashkelon, , Israel
Soroka Medical Center; Gastroenterology
Beersheba, , Israel
Hillel Yaffe Hospital; Gastroenterology
Hadera, , Israel
Rambam Medical Center; Gastroenterology - Liver Unit
Haifa, , Israel
Bnei-Zion Medical Center; Gastroenterology
Haifa, , Israel
Carmel Hospital; Liver Unit
Haifa, , Israel
Wolfson Hospital; Gastroenterology Unit
Holon, , Israel
Shaare Zedek Hospital Liver Unit; Liver Unit
Jerusalem, , Israel
Hadassah Hospital; Liver Unit
Jerusalem, , Israel
Meir Medical Center; Liver Unit
Kfar Saba, , Israel
Western Galilee Hospital - Nahariya
Nahariya, , Israel
Holy Family Medical Center; Liver Unit
Nazareth, , Israel
Beilinson-Rabin Liver Unit; Liver Unit
Petah Tikva, , Israel
Hasharon Mc; Gastroenterology
Petah Tikva, , Israel
Sheba Medical Center; Tel Hashomer
Ramat Gan, , Israel
Kaplan Medical Center; Gastroenterology Unit
Rehovot, , Israel
Tel-Aviv Sourasky Medical Center; Liver Unit
Tel Aviv, , Israel
Poria Hospital; Gastroenterology
Tiberias, , Israel
Assaf Harofeh; Gastroenterology
Ẕerifin, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML28268
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.